Scientific Letters
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Sustained Complete Response to a Short Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 1, 2026
0
Views
0
Downloads
Authors
A woman with primary immune thrombocytopenia (ITP) refractory to corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and two thrombopoietin receptor agonists (TPO-RAs) received a new therapy.
Downloads
Download data is not yet available.
Citations
Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, Li H, Liu X, Fu R, Ju M, Xue F, Liu W, Dong H, Gu W, Dai X, Wang W, Chi Y, Pei X, Yang R, Zhang L. Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. EClinicalMedicine. 2026;94:103849. https://doi.org/10.1016/j.eclinm.2026.103849
2. Patel PS, Farrugia S, Nunnelee J, Mina S, Godby RC, Go R, Rajkumar SV. Efficacy of CD38-targeted therapy in severe, multi-agent refractory immune thrombocytopenia: a case series. Eur J Haematol. 2026;117(1):279-282. https://doi.org/10.1111/ejh.70180
3. Hu Y, Chen H, Wang Z, Ma J, Dong S, Lin X, Cheng X, Bussel JB, Chen Z, Wu R. Daratumumab in pediatric chronic refractory primary immune thrombocytopenia (ITP): rapid platelet recovery, sustained response, and immune reconstitution dynamics. Am J Hematol. 2026;101(2):384-387. https://doi.org/10.1002/ajh.70148
4. Al-Mashdali AF, Dalol AA, Saleh LH, Aweer RA, Abdulgayoom M, Cherif H, Mohamed SF. Targeting CD38 in immune thrombocytopenia: rationale and a scoping review of daratumumab. Blood Rev. 2026:101409. https://doi.org/10.1016/j.blre.2026.101409
5. Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjønnfjord E, Munthe LA, Drivet E, Kared H, Sørvoll IH, Ahlen MT, Mahévas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W. Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv. 2026;10(1):143-154. https://doi.org/10.1182/bloodadvances.2025017279
Ethics Approval
Immune thrombocytopenia (ITP). Autoimmune hematologic disorders. Biologic therapies. Thrombopoietin receptor agonists. FcRn inhibitors. B-cell targeted therapy. Treatment sequencing. HematologySupporting Agencies
NoneHow to Cite
“Sustained Complete Response to a Short Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026069. doi:10.4084/MJHID.2026.069.
Copyright (c) 2026 Tuba Gullu koca, Ahmet Mert Yanik
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
